Myriad Genetics (MYGN)
(Real Time Quote from BATS)
$25.52 USD
+0.27 (1.07%)
Updated May 10, 2024 12:30 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Brokerage Reports
Myriad Genetics, Inc. [MYGN]
Reports for Purchase
Showing records 221 - 240 ( 241 total )
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
F3Q11 Results Review: Lots to Like: Growth, Acquisition, and European Expansion
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Incremental Growth Drivers Lead Us to Increase Estimates and Price Target
Provider: AURIGA USA
Analyst: MEHRA R
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Lab Industry Alert: Attending 28th Annual Lab Institute 2010 Conference.
Provider: KAUFMAN BROTHERS
Analyst: BROCK D
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
In Today''s Morning Exchange
Provider: KAUFMAN BROTHERS
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
What could be the Impact on Diagnostic Companies from a Re-Invigorated FDA?
Provider: AURIGA USA
Analyst: MEHRA R
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
The Bar Has Been Reset - Upgrading Rating to BUY and Increasing Price Target to $23
Provider: AURIGA USA
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
F3Q10 Results Review: Too Many Headwinds.
Provider: AURIGA USA
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Initiate With a Sell rating
Provider: AURIGA USA
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Beat on Top and Bottom Line; Poised for Potential Turnaround in H2.
Provider: WEDBUSH SECURITIES INC.
Analyst: LEE K